67268 Federal Register / Vol. 66, No. 249 / Friday, December 28, 2001 / Notices

and county column, delete ‘‘King’’, in

the FY 2002 funding level column

delete ‘‘805,124’’ and in the Service area

column delete ‘‘City of Seattle: Yesler

Terrace, Holly Park, High Point and

Ranier Vista Public Housing Districts’’.

On page 48476, Appendix A, Part II,

in the State of Washington, in the State

and county Column delete ‘‘None’’ and

add the county of ‘‘King’’, in the FY

2002 funding level column add

‘‘805,124’’, and in the Service area

column add ‘‘City of Seattle: Yesler

Terrace, Holly Park, High Point, and

Ranier Vista Public Housing Districts’’.

FOR FURTHER INFORMATION CONTACT: The

ACYF Operations Center at 1–800–351–

2293 or send an email to

ehs@lcgnet.com. You can also contact

Sherri Ash, Early Head Start, Head Start

Bureau at (202) 205–8562.

Dated: December 20, 2001.

James A. Harrell,

Acting Commissioner, Administration on

Children, Youth and Families.

[FR Doc. 01–31884 Filed 12–27–01; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Cardiovascular and Renal Drugs

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

This notice announces a forthcoming

meeting of a public advisory committee

of the Food and Drug Administration

(FDA). The meeting will be open to the

public.

Name of Committee: Cardiovascular

and Renal Drugs Advisory Committee.

General Function of the Committee:

To provide advice and

recommendations to the agency on

FDA’s regulatory issues.

Date and Time: The meeting will be

held on January 17 and 18, 2002, from

8:30 a.m. to 4:30 p.m.

Location: Holiday Inn, Kennedy

Ballroom, 8777 Georgia Ave., Silver

Spring, MD.

Contact: Jaime Henriquez, Center for

Drug Evaluation and Research, (HFD–

21), Food and Drug Administration,

5600 Fishers Lane (for express delivery,

5630 Fishers Lane, rm. 1093), Rockville,

MD 20857, 301–827–7001 or FDA

Advisory Committee Information Line,

1–800–741–8138 (301–443–0572 in the

Washington, DC area), code 12533.

Please call the Information Line for upto-date information on this meeting.

Agenda: On January 17, 2002, the

committee will discuss new drug

application (NDA) 20–757/S–021,

AVAPRO (irbesartan), SanofiSynthelabo (c/o Bristol-Myers Squibb),

for the treatment of hypertensive

patients with type 2 diabetic renal

disease. On January 18, 2002, the

committee will discuss NDA 21–387,

pravastatin/aspirin, Bristol-Myers

Squibb, co-package, for long-term

management to reduce the risk of death,

nonfatal myocardial infarction,

myocardial revascularization

procedures, and ischemic stroke in

patients with clinically evident

coronary heart disease.

Procedure: Interested persons may

present data, information, or views,

orally or in writing, on issues pending

before the committee. Written

submissions may be made to the contact

person by January 7, 2002. Oral

presentations from the public will be

scheduled each day between

approximately 1 p.m. and 2 p.m. Time

allotted for each presentation may be

limited. Those desiring to make formal

oral presentations should notify the

contact person before January 7, 2002,

and submit a brief statement of the

general nature of the evidence or

arguments they wish to present, the

names and addresses of proposed

participants, and an indication of the

approximate time requested to make

their presentation.

Notice of this meeting is given under

the Federal Advisory Committee Act (5

U.S.C. app. 2).

Dated: December 14, 2001.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 01–31879 Filed 12–27–01; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Pulmonary-Allergy Drugs Advisory

Committee; Notice of Meeting

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

This notice announces a forthcoming

meeting of a public advisory committee

of the Food and Drug Administration

(FDA). At least one portion of the

meeting will be closed to the public.

Name of Committee: PulmonaryAllergy Drugs Advisory Committee.

General Function of the Committee:

To provide advice and

recommendations to the agency on

FDA’s regulatory issues.

Date and Time: The meeting will be

held on January 17, 2002, from 8 a.m.

to 5 p.m., and January 18, 2002, from 8

a.m. to 3 p.m.

Location: Holiday Inn, The Ballrooms,

Two Montgomery Village Ave.,

Gaithersburg, MD.

Contact: Kimberly L. Topper, Center

for Drug Evaluation and Research (HFD–

21), Food and Drug Administration,

5600 Fishers Lane (for express delivery,

5630 Fishers Lane, rm. 1093), Rockville,

MD 20857, 301–827–7001, or FDA

Advisory Committee Information Line,

1–800–741–8138 (301–443–0572 in the

Washington, DC area), code 12545.

Please call the Information Line for upto-date information on this meeting.

Agenda: On January 17, 2002, the

committee will discuss the use of two

new drug applications (NDAs): NDA

20–833, Flovent Diskus, and NDA 21–

077, Advair Diskus, GlaxoSmithKline,

as maintenance therapy in patients with

chronic obstructive pulmonary disease

(COPD). On January 18, 2002, the

meeting will be open to the public from

8 a.m. to 9 a.m., unless public

participation does not last that long;

from 9 a.m. to 3 p.m., the meeting will

be closed to permit discussion and

review of trade secret and/or

confidential information.

Procedure: On January 17, 2002, from

8 a.m. to 5 p.m. and on January 18,

2002, from 8 a.m. to 9 a.m., the meeting

will be open to the public. Interested

persons may present data, information,

or views, orally or in writing, on issues

pending before the committee. Written

submissions may be made to the contact

person by January 11, 2002. Oral

presentations from the public will be

scheduled between approximately 1

p.m. and 2 p.m. on January 17, 2002,

and between approximately 8 a.m. and

9 a.m. on January 18, 2002. Time

allotted for each presentation may be

limited. Those desiring to make formal

oral presentations should notify the

contact person before January 11, 2002,

and submit a brief statement of the

general nature of the evidence or

arguments they wish to present, the

names and addresses of proposed

participants, and an indication of the

approximate time requested to make

their presentation.

Closed Committee Deliberations: On

January 18, 2002, from 9 a.m. to 3 p.m.,

the meeting will be closed to permit

discussion and review of trade secret

and/or confidential information (5

U.S.C. 552b(c)(4)).

Notice of this meeting is given under

the Federal Advisory Committee Act (5

U.S.C. app. 2).

Federal Register / Vol. 66, No. 249 / Friday, December 28, 2001 / Notices 67269

Dated: December 19, 2001.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 01–31878 Filed 12–27–01; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Health Resources and Services

Administration

Agency Information Collection

Activities: Proposed Collection:

Comment Request

In compliance with the requirement

for opportunity for public comment on

proposed data collection projects

(section 3506(c)(2)(A) of Title 44, United

States Code, as amended by the

Paperwork Reduction Act of 1995,

Public Law 104–13), the Health

Resources and Services Administration

(HRSA) publishes periodic summaries

of proposed projects being developed

for submission to OMB under the

Paperwork Reduction Act of 1995. To

request more information on the

proposed project or to obtain a copy of

the data collection plans and draft

instruments, call the HRSA Reports

Clearance Officer on (301) 443–1891.

Comments are invited on: (a) Whether

the proposed collection of information

is necessary for the proper performance

of the functions of the agency, including

whether the information shall have

practical utility; (b) the accuracy of the

agency’s estimate of the burden of the

proposed collection of information; (c)

ways to enhance the quality, utility, and

clarity of the information to be

collected; and (d) ways to minimize the

burden of the collection of information

on respondents, including through the

use of automated collection techniques

or other forms of information

technology.

Proposed Project: Implement

performance standards for Special

Projects of Regional or National

Significance (SPRANS), Community

Integrated Service Systems (CISS)

projects, and other grant programs

administered by MCHB.

The Health Resources and Services

Administration (HRSA) proposes to

modify reporting requirements for

SPRANS projects, CISS projects, and

other grant programs administered by

the Maternal and Child Health Bureau

(MCHB) to include national

performance measures being developed

in accordance with the requirements of

the ‘‘Government Performance and

Results Act (GPRA) of 1993’’ (Public

Law 103–62). This act requires the

establishment of measurable goals for

Federal programs that can be reported as

part of the budgetary process, thus

linking funding decisions with

performance. Performance measures for

States have already been established

under the block grant provisions of Title

V. Performance measures for other

MCHB-funded grant programs are

currently being finalized, and will be

sent to the Office of Management and

Budget for approval.

There are approximately 30 proposed

new performance measures. However,

some measures are specific to certain

types of programs, and will not apply to

all grantees. Furthermore, the measures

are expected to be based primarily on

existing data. Thus, response burden

associated with this proposed

requirement will be minimal. The

estimated response burden is as follows:

Type of form Number of respondents

Responses per

respondent

Burden hours

per response

Total burden

hours

Application and Annual Report ................................................................ 750 1 8 6,000

Send comments to Susan G. Queen,

Ph.D., HRSA Reports Clearance Officer,

Room 11–05, Parklawn Building, 5600

Fishers Lane, Rockville, MD 20857.

Written comments should be received

within 60 days of this notice.

Dated: December 20, 2001.

Jane Harrison,

Director, Division of Policy Review and

Coordination.

[FR Doc. 01–31898 Filed 12–27–01; 8:45 am]

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Health Resources and Services

Administration

Agency Information Collection

Activities: Submission for OMB

Review; Comment Request

Periodically, the Health Resources

and Services Administration (HRSA)

publishes abstracts of information

collection requests under review by the

Office of Management and Budget, in

compliance with the Paperwork

Reduction Act of 1995 (44 U.S.C.

Chapter 35). To request a copy of the

clearance requests submitted to OMB for

review, call the HRSA Reports

Clearance Office on (301) 443–1129.

The following request has been

submitted to the Office of Management

and Budget for review under the

Paperwork Reduction Act of 1995:

Proposed Project: Ryan White CARE

Act Dental Reimbursement Program

(OMB No. 0915–0151)—Revision

The Dental Reimbursement Program

(DRP) under Part F of the Ryan White

CARE Act offers grants to accredited

dental schools and programs that

provide non-reimbursed oral health care

to patients with HIV disease. The Ryan

White CARE Act Amendments of 2000

expanded eligibility of this program to

accredited schools of dental hygiene, in

addition to previously funded schools of

dentistry and post-doctoral dental

education programs.

HRSA requests a revision to the DRP

Application that schools and programs

use to apply for funding of nonreimbursed costs incurred in providing

oral health care to patients with HIV.

Awards are authorized under section

776(b) of the Public Health Service Act

(42 U.S.C. 294n). The 2001 DRP

Application is intended to collect data

in three different areas: program

information, patient demographics and

services, and reimbursement and

funding. It also requests applicants to

provide narrative descriptions of their

services and facilities, as well as their

links and collaboration with

community-based providers of oral

health services.

The primary purpose of collecting this

information annually, as part of the DRP

Application, is to verify eligibility and

determine the reimbursement amount

each applicant should receive. This

information also allows HRSA to learn

about (1) the extent of the involvement

of dental schools and programs in

treating patients with HIV, (2) the

number and characteristics of clients

who receive CARE Act-supported oral

health services, (3) the types and

frequency of the provision of these

services, (4) the non-reimbursed costs of

oral health care provided to patients

with HIV, and (5) how applicants intend

to use DRP funds once they are

received. In addition to meeting the goal

of accountability to Congress, clients,

advocacy groups, and the general

public, information collected in the DRP